A recent Pfizer-led decentralized trial using a BYOD mobile app revealed that subtle changes in voice biomarkers can indicate early signs of respiratory illness. The study used machine learning to analyze MFCC features and baseline differences, suggesting a promising digital method for early disease detection.

Q&A

  • What is a decentralized clinical trial?
  • How does baseline subtraction in the tangent space work?
  • How does voice biomarker detection differ from conventional tests?
Copy link
Facebook X LinkedIn WhatsApp
Share post via...


Read full article